Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
Auditor change
Appointed director
|
|
IMMUNOMEDICS INC (IMMU)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 10/12/2020 |
GN
| Immunomedics Announces FDA Orphan Drug Designation of Trodelvy™ for Adult and Pediatric Glioblastoma |
| 09/22/2020 |
GN
| SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Reminds Investors of Investigations of IMMU, VRTU, RST, and CBMG Buyouts |
| 09/19/2020 |
GN
| Immunomedics Announces Positive Results from Pivotal Phase 2 TROPHY U-01 Study of Trodelvy™ in Metastatic Urothelial Cancer |
| 09/19/2020 |
GN
| Trodelvy™ Significantly Extends Survival in Phase 3 ASCENT Study of Metastatic Triple-Negative Breast Cancer |
| 09/18/2020 |
GN
| Immunomedics Announces Encouraging Early-Stage Clinical Results with Trodelvy™ in Brain Cancers |
| 09/14/2020 |
GN
| SHAREHOLDER ALERT: Rigrodsky & Long, P.A. Announces Investigation of Immunomedics, Inc. Buyout |
| 09/02/2020 |
GN
| Immunomedics to Participate in Upcoming Healthcare Conferences |
| 08/17/2020 |
GN
| Immunomedics Announces FDA Approval of Samsung Biologics as Antibody Manufacturer for Trodelvy™ |
| 08/05/2020 |
GN
| Immunomedics Reports Second Quarter 2020 Results and Provides Corporate Update |
| 06/05/2020 |
GN
| Lifshitz Law Firm, P.C. Announces Investigation of Apyx Medical Corporation (APYX), Honeywell International Inc. (HON), Immunomedics, Inc. (IMMU), and Zuora, Inc. (ZUO) |
| 05/28/2020 |
GN
| Immunomedics to Participate in Upcoming Healthcare Conferences |
| 05/27/2020 |
GN
| Immunomedics Announces Leadership Change and Provides Business Update Amid COVID-19 |
| 05/07/2020 |
GN
| Immunomedics to Participate in BofA Securities 2020 Health Care Conference |
| 05/01/2020 |
GN
| Immunomedics Announces Closing Of Public Offering Of Common Stock |
| 04/28/2020 |
GN
| Immunomedics Announces Pricing of Public Offering of Common Stock |
| 04/24/2020 |
GN
| CORRECTION: Everest Medicines Announces That Licensing Partner Immunomedics has Received FDA Accelerated Approval for Trodelvy (sacituzumab govitecan-hziy) in Previously-treated Metastatic Triple-Negative Breast Cancer |
| 04/24/2020 |
GN
| ?????????????Immunomedics??Trodelvy (sacituzumab govitecan-hziy)?????????????????,???????????????????? |
| 04/22/2020 |
GN
| FDA Grants Accelerated Approval for Immunomedics' Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer |
| 04/07/2020 |
GN
| CORRECTION - FDA GRANTS FAST TRACK DESIGNATION TO SACITUZUMAB GOVITECAN FOR LOCALLY-ADVANCED OR METASTATIC UROTHELIAL CANCER |
| 04/06/2020 |
GN
| IMMUNOMEDICS ANNOUNCES EXECUTIVE LEADERSHIP CHANGES AND THE APPOINTMENT OF HAROUT SEMERJIAN AS PRESIDENT AND CHIEF EXECUTIVE OFFICER |
| 04/03/2020 |
GN
| IMMUNOMEDICS TO HOST CONFERENCE CALL AND WEBCAST ON APRIL 6, 2020 TO PROVIDE CLINICAL AND CORPORATE UPDATE |
| 03/25/2020 |
GN
| IMMUNOMEDICS PROVIDES COVID-19 BUSINESS CONTINUITY UPDATE, AFFIRMS 2020 STRATEGIC PRIORITIES, AND SHARES R&D AND REGULATORY UPDATE |
| 02/27/2020 |
GN
| Immunomedics Appoints Robert W. Azelby to Board of Directors |
| 02/27/2020 |
GN
| Immunomedics Reports Fourth Quarter and Full Year 2019 Results and Provides Corporate Update |
| 12/09/2019 |
GN
| Immunomedics Announces Closing of Public Offering of Common Stock |
| 12/04/2019 |
GN
| Immunomedics Announces Pricing of Public Offering of Common Stock |
| 12/03/2019 |
GN
| Immunomedics Announces Proposed Public Offering of Common Stock |
| 12/03/2019 |
GN
| Immunomedics Resubmits Biologics License Application to the FDA for Sacituzumab Govitecan |
| 11/13/2019 |
GN
| Immunomedics to Present at Upcoming Healthcare Conferences |
| 10/23/2019 |
GN
| Immunomedics to Report Third Quarter 2019 Results and Host Conference Call and Webcast on October 30, 2019 |
| 09/28/2019 |
GN
| Immunomedics Provides Corporate Update |
| 09/12/2019 |
GN
| Immunomedics to Host Investor Event and Webcast on September 28, 2019 During ESMO Congress |
| 09/05/2019 |
GN
| Bragar Eagel & Squire is Investigating Certain Officers and Directors of MGT Capital Investments, First American Financial, Immunomedics, and AAC Holdings and Encourages Investors to Contact the Firm |
| 09/04/2019 |
GN
| Immunomedics Announces Oral Presentation of Sacituzumab Govitecan in Metastatic Urothelial Cancer at ESMO 2019 Annual Congress |
|
|
|